Search Result

Isoforms Recommended:	FR-α

Results for "

FRα

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (1) Antibody-Drug Conjugates (ADCs) (2) Antifolate (6) Drug-Linker Conjugates for ADC (1) Fluorescent Dye (2) Folate Receptor (FR) (6) Peptide-Drug Conjugates (PDCs) (1) TRP Channel (1)
By Research Areas:	Cancer (14)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Recombinant Proteins

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-132258A

Mirvetuximab soravtansine (solution) 3 Publications Verification IMGN853 (solution)	Antibody-Drug Conjugates (ADCs) Antifolate	Cancer
Mirvetuximab soravtansine (IMGN853) solution is an anti-folate receptor α (FRα) antibody drug-conjugate (ADC) consisting of the cytotoxic maytansinoid, DM4, covalently linked to the humanized monoclonal antibody M9346A, and the drug-linker conjugate for ADC is sulfo-SPDB-DM4 (HY-101141). Mirvetuximab soravtansine selectively binds to folate receptor 1 (FOLR1). Mirvetuximab soravtansine has an anti-proliferative effect via growth arrest and augmented DNA damage .

HY-P99153

Farletuzumab MORAb-003	Antibiotic	Cancer
Farletuzumab (MORAb-003) is a potent folate receptor-alpha (FRα) inhibitor. Farletuzumab is a humanized monoclonal antibody with high affinity for FRα. Farletuzumab possesses growth-inhibitory functions on cells overexpressing FRα. Farletuzumab can be used in research of cancer .

HY-13615A

EC-17 disodium salt 1 Publications Verification	Fluorescent Dye Folate Receptor (FR)	Cancer
EC-17 disodium salt is a folate receptor alpha (FRα) targeting contrast agent with fluorescent properties in the visible light spectrum. The EC-17 maximum excitation and emission wavelengths are 490 nm and 520 nm, respectively .

HY-13615

Folate-FITC EC-17	Fluorescent Dye Folate Receptor (FR)	Cancer
Folate-FITC (EC-17) is a folate receptor alpha (FRα) targeting contrast agent with fluorescent properties in the visible light spectrum. The Folate-FITC maximum excitation and emission wavelengths are 490 nm and 520 nm, respectively .

HY-P10762

Ricorfotide vedotin CBP-1008; LDC 10B	Peptide-Drug Conjugates (PDCs) Folate Receptor (FR) TRP Channel	Cancer
Ricorfotide vedotin (CBP-1008) is a dual-ligand peptide-drug conjugate (PDC) conjugated to MMAE (HY-15162), targeting Folate receptor α (FRα) and TRPV6. Ricorfotide vedotin binds to FRα with high affinity and TRPV6 with low affinity. Ricorfotide vedotin has antitumor activity, and can be used in advanced solid tumor research (eg: colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer, adrenocortical carcinoma and follicular dendritic cell sarcoma) .

HY-156515

MC-GGFG-(7ethanol-10NH2-11F-Camptothecin)	Drug-Linker Conjugates for ADC	Cancer
MC-GGFG-(7ethanol-10NH2-11F-Camptothecin) is a drug-linker conjugate for ADC, formed by conjugation of 7ethanol-10NH2-11F-Camptothecin (HY-156517) with the protease-cleavable MC-GGFG linker. MC-GGFG-(7ethanol-10NH2-11F-Camptothecin) is applicable for cancer research .

HY-P10501A

FRα-targeting peptide C7 TFA	Antifolate	Cancer
FRα-targeting peptide C7 TFA is a selective peptide ligand for folate receptor α (FRα) that has specific binding to FRα expressing cells and in vivo tumor targeting ability. FRα-targeting peptide C7 TFA can be used in the research of tumor diagnosis and treatment .

HY-175428

Antifolate agent 1	Antifolate	Cancer
Antifolate agent 1 is a 6-substituted pyrrolopyrimidine antifolate with a 1-carbon bridge. Antifolate agent 1 shows no activity against cells expressing *FRα* and FRβ, and has no GARFTase inhibitory activity. Antifolate agent 1 can be used as a negative control in the development of folate receptor-targeted antifolates .

HY-P10501

FRα-targeting peptide C7	Antifolate	Cancer
FRα-targeting peptide C7 is a selective peptide ligand for folate receptor α (FRα) that has specific binding to FRα expressing cells and in vivo tumor targeting ability. FRα-targeting peptide C7 can be used in the research of tumor diagnosis and treatment .

HY-147699

FRα-IN-1	Antifolate	Cancer
FRα-IN-1 (Compound 4) is a tumor-targeting agent. FRα-IN-1 shows selective anticancer activity towards folate receptors (FRα and FRβ) expression cells .

HY-157217

Antitumor agent-99	Antifolate	Cancer
Antitumor agent-99 (compound 7) is an anticancer agent targeting FRα/β and PCFT. Antitumor agent-99 inhibits R2/PCFT4 (PCFT), RT16(FRα), and D4(FRβ) cells with IC₅₀s of 51.46 nM, 2.53 nM, and 2.98 nM, respectively .

HY-185427

Opugotamig olatansine IMGN-151	Antibody-Drug Conjugates (ADCs) Folate Receptor (FR)	Cancer
Opugotamig olatansine (IMGN151) is a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC). Opugotamig olatansine comprises antibody Opugotamig (HY-P990935) and linker-payload NMS-P945 (HY-185569). Opugotamig olatansine binds to two independent epitopes of FRα and promotes antibody binding, internalization, and processing. Opugotamig olatansine can be used for the research of FRα-positive ovarian cancer .

HY-P992124

Onvontatug BAT8006 Antibody; BAT-6028	Folate Receptor (FR)	Cancer
Onvontatug (BAT8006 Antibody) is a humanized monoclonal antibody targeting folate receptor α (FRα). Onvontatug can be used to construct antibody-drug conjugates (ADCs), such as BAT8006. It is applicable to research related to platinum-resistant ovarian cancer .

HY-180557

4A-BFA-11	Folate Receptor (FR)	Cancer
4A-BFA-11 is a folate-targeted PEG-MMAE conjugate that exhibits specific binding affinity for the folate receptor α (FR-α) (K_D = 106.7 nM). 4A-BFA-11 achieves tumor enrichment by combining PEG-mediated long circulation (EPR effect) and folate receptor targeting. 4A-BFA-11 undergoes enzymatic cleavage at the tumor site to release the active payload, enabling precise action. 4A-BFA-11 sefficiently carries, targets, and controls the release of MMAE in tumor tissues in a HeLa mouse model. 4A-BFA-11 can be used for cervical cancer, ovarian cancer, and lung cancer research .

Cat. No.	Product Name	Target	Research Area

HY-P10762

Ricorfotide vedotin CBP-1008; LDC 10B	Peptide-Drug Conjugates (PDCs) Folate Receptor (FR) TRP Channel	Cancer
Ricorfotide vedotin (CBP-1008) is a dual-ligand peptide-drug conjugate (PDC) conjugated to MMAE (HY-15162), targeting Folate receptor α (FRα) and TRPV6. Ricorfotide vedotin binds to FRα with high affinity and TRPV6 with low affinity. Ricorfotide vedotin has antitumor activity, and can be used in advanced solid tumor research (eg: colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer, adrenocortical carcinoma and follicular dendritic cell sarcoma) .

HY-P10501A

FRα-targeting peptide C7 TFA	Antifolate	Cancer
FRα-targeting peptide C7 TFA is a selective peptide ligand for folate receptor α (FRα) that has specific binding to FRα expressing cells and in vivo tumor targeting ability. FRα-targeting peptide C7 TFA can be used in the research of tumor diagnosis and treatment .

HY-P10501

FRα-targeting peptide C7	Antifolate	Cancer
FRα-targeting peptide C7 is a selective peptide ligand for folate receptor α (FRα) that has specific binding to FRα expressing cells and in vivo tumor targeting ability. FRα-targeting peptide C7 can be used in the research of tumor diagnosis and treatment .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99153

Farletuzumab MORAb-003	Antibiotic	Cancer
Farletuzumab (MORAb-003) is a potent folate receptor-alpha (FRα) inhibitor. Farletuzumab is a humanized monoclonal antibody with high affinity for FRα. Farletuzumab possesses growth-inhibitory functions on cells overexpressing FRα. Farletuzumab can be used in research of cancer .

HY-P992124

Onvontatug BAT8006 Antibody; BAT-6028	Folate Receptor (FR)	Cancer
Onvontatug (BAT8006 Antibody) is a humanized monoclonal antibody targeting folate receptor α (FRα). Onvontatug can be used to construct antibody-drug conjugates (ADCs), such as BAT8006. It is applicable to research related to platinum-resistant ovarian cancer .

Species:	Human (2)
Tag:	His (2) Avi (1)
Source:	HEK293 (2)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P701278

	FITC-Labeled FOLR1 Protein, Human (HEK293, His) FOLR-1; FBP; FOLR; FRα	Human	HEK293
	The FOLR1 protein is an important mediator of folate uptake, binding to folate and promoting the delivery of 5-methyltetrahydrofolate into cells. Studies show high affinity at neutral pH. FITC-Labeled FOLR1 Protein, Human (HEK293, His) is the recombinant human-derived FITC-Labeled FOLR1 protein, expressed by HEK293 , with His labeled tag.

HY-P705524

	FITC-Labeled FOLR1 Protein, Human (HEK293, His-Avi) FOLR-1; FBP; FOLR; FRα	Human	HEK293
	The FOLR1 protein is an important mediator of folate uptake, binding to folate and promoting the delivery of 5-methyltetrahydrofolate into cells. Studies show high affinity at neutral pH. FITC-Labeled FOLR1 Protein, Human (HEK293, His-Avi) is the recombinant human-derived FITC-Labeled FOLR1 protein, expressed by HEK293 , with C-His-Avi labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.